Justin M. Watts, MD, discusses the potential advantages of the oral small molecule BET inhibitor INCB057643 in advanced myelofibrosis.
Justin M. Watts, MD
Advertisement
Articles by Justin M. Watts, MD
Justin M. Watts, MD, discusses the final 5-year results of the 2102-HEM-101 trial of olutasidenib in patients with IDH1-mutated acute myeloid leukemia.
Justin M. Watts, MD, discusses the design and purpose of a phase 1 trial evaluating INCB057643 in myelofibrosis and other advanced myeloid neoplasms.
Justin M. Watts, MD, discusses the safety profile and tolerability of INCB057643 in patients with myelofibrosis.
Advertisement
Latest Updated Articles
Dr Watts on the Potential Advantages of INCB057643 in Advanced MyelofibrosisPublished: November 27th 2024 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
2
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
3
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
4
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
5